Friday, 19 June 2026

Vol. 1 · No. 17 Friday, 19 June 2026 “The record is not what we fear — it is what we failed to prevent.”

In this edition

This edition leads with the first population-level evidence that HPV vaccination can drive cervical cancer mortality to zero: a Lancet analysis finds no cervical cancer deaths in England's 88–90% coverage birth cohort over a five-year window, with an 80% reduction in catch-up cohorts and 69% in the 25–29 age group. The SNAP trial in The Lancet finds benzylpenicillin reduces AKI by half versus flucloxacillin in PSSA bacteraemia, despite a missed primary non-inferiority threshold (96.1% Bayesian posterior probability). FDA reverses course on uniQure's AMT-130, agreeing Phase I/II data can support a BLA under Accelerated Approval for Huntington's disease with standard-of-care comparator in the confirmatory trial. BDBV Ebola confirmed cases rise to 837 in DRC/Uganda as the WHO PHEIC remains active. Apellis suspends Phase 3 kidney transplant trial for pegcetacoplan with no posted reason. U.S. measles cases reach 2,104 as PAHO postpones elimination re-evaluation. FDA clears first generic baloxavir marboxil. A Nature study shows autonomous AI agent MIRA surpasses physicians in sandboxed EHR simulations.

Research

HPV Vaccination Associated With Zero Cervical Cancer Deaths in England's Highest-Coverage Birth Cohort, Lancet Study Finds

A population cohort analysis of England's national cervical cancer registry and death records finds no cervical cancer deaths in women with 88–90% HPV vaccine coverage over a five-year follow-up window, with an 80% mortality reduction in catch-up cohorts and 69% in the 25–29 age group — the first mortality-endpoint evidence from a national HPV programme.

Science & Research Desk · 4 min read

A population-level study published in The Lancet on June 19, 2026, has found zero cervical cancer deaths among women in England’s highest-coverage HPV-vaccinated birth cohort over a five-year follow-up window — the first evidence that HPV vaccination can drive cervical cancer mortality to zero in a real-world national cohort.

The study, led by Peter Sasieni (Wolfson Institute of Population Health, Queen Mary University of London) and Alejandra Falcaro, tracked cervical cancer mortality in English women by birth cohort according to the timing and coverage of the NHS HPV vaccination program launched in 2008. Among the cohort with vaccine coverage of 88–90% — those who received the jab through the school-based program at ages 12–13 — no cervical cancer deaths were recorded during the five-year observation window (women aged 20–24 in 2020–24). The authors report an 80% reduction in cervical cancer mortality in women aged 20–24 in 2015–19 (a period capturing the first routinely vaccinated cohorts as well as catch-up recipients), and a 69% reduction among women aged 25–29 in 2020–24, each compared with modelled expected mortality in the absence of vaccination.

Continue reading →

Also leading today

Opinion

Zero Cervical Cancer Deaths: A Milestone That Demands Acceleration

England's zero-mortality finding in its highest-coverage HPV cohort is the mortality endpoint advocates have waited 18 years for. The caveats are real; so is the urgency for the countries that cannot yet replicate England's coverage.

The Vital Record · Editorial · 3 min

Clinical Trials

Benzylpenicillin Misses Formal Non-Inferiority Threshold but Halves Kidney Injury in PSSA Bacteraemia — SNAP Trial

The SNAP trial reports a 96.1% Bayesian posterior probability of non-inferiority for benzylpenicillin versus flucloxacillin in Staphylococcus aureus bacteraemia and a halving of acute kidney injury — but formally misses the pre-specified non-inferiority threshold.

Clinical Trials Desk · 3 min

In brief

FDA & Regulatory FDA Agrees AMT-130 Phase I/II Data Can Support a BLA for Huntington's Disease Under Accelerated Approval A Type B meeting outcome announced June 17, 2026 marks a second reversal by FDA: after demanding a sham-surgery-controlled Phase 3 in November 2025 and reaffirming that position in March 2026, the agency now agrees uniQure can file a BLA for the gene therapy AMT-130 on three-year Phase I/II data under Accelerated Approval — with a standard-of-care comparator in the confirmatory trial.
Public Health Ebola Bundibugyo Confirmed Cases Rise to 837 in DRC and Uganda — WHO PHEIC Remains Active ECDC Week 25 situational data confirm 837 Ebola Bundibugyo virus (BDBV) confirmed cases across DRC and Uganda. No licensed BDBV vaccine exists. WHO PHEIC declared May 17 remains active.
Biotech Business Apellis Halts Phase 3 Kidney Transplant Trial for Pegcetacoplan With No Posted Reason Apellis Pharmaceuticals suspended enrollment in NCT07020832, a Phase 3 trial of pegcetacoplan in kidney transplant recipients, approximately five weeks after the trial opened — with no public explanation from the company.
Public Health U.S. Measles Cases Top 2,100 in 2026 — CDC Reports Largest Modern Outbreak as PAHO Defers Elimination Re-Evaluation The CDC's June 18 weekly update records 2,104 confirmed measles cases in the United States in 2026, the highest annual total in at least 30 years. PAHO has postponed its planned Americas-wide elimination re-evaluation.
Digital Health & AI Autonomous AI Agent Navigates EHR, Surpasses Physicians in Simulated Cases — Nature A Nature paper reports that MIRA, an autonomous AI agent operating across a full electronic health record interface without human assistance, outperformed board-certified attending physicians on complex inpatient case simulations — the first agentic EHR system to do so in a peer-reviewed large-cohort evaluation.
FDA & Regulatory FDA Approves First Generic Baloxavir, Broadening Access to Single-Dose Flu Treatment Norwich Pharmaceuticals received FDA approval on June 17, 2026 for the first generic baloxavir marboxil — a single-dose oral influenza antiviral — opening competition with Roche's branded Xofluza for the first time.

← The archive

Friday, 19 June 2026 edition — The Vital Record

HPV Vaccination Associated With Zero Cervical Cancer Deaths in England's Highest-Coverage Birth Cohort, Lancet Study Finds

Also leading today

Zero Cervical Cancer Deaths: A Milestone That Demands Acceleration

Benzylpenicillin Misses Formal Non-Inferiority Threshold but Halves Kidney Injury in PSSA Bacteraemia — SNAP Trial

In brief